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Abstract In human body fluids a soluble form of the 
interleukin-6 receptor (sIL-6R) has been found which together 
with interleukin-6 (IL-6) acts agonistically on cells expressing 
the signal transducer gp130. The means by which the sIL-6R is 
removed from the circulation is unknown. Here, we show that a 
complex of 1251-labelled recombinant sIL-6R and IL-6 is 
internalized by MDCK cells stably transfected with gp130 and 
by human hepatoma cells HepG2 that endogenously express the 
IL-6R and gp130. We further show that most of the internalized 
sIL-6R is degraded within lysosomes. Our studies suggest that 
cells expressing gp130 are capable of endocytosing an IL-6/sIL- 
6R complex, thereby removing both from the circulation. 
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1. Introduction 
The interleukin-6 receptor complex comprises two subunits, 
an 80 kDa IL-6 binding protein (IL-6 receptor) and a 130 
kDa signal transducing protein, gp130 [l-3]. Binding of IL-6 
to its receptor leads to the formation of a gp130 dimer which 
transduces the signal into the cell [4]. For this process the 
cytoplasmic domain of gp130 was found to be essential [5]. 
In contrast, the intracellular as well as the transmembrane 
domain of the IL-6 receptor is not necessary for signalling 
[2,6,7]. Such soluble IL-6 receptors (sIL-6R) are found in 
body fluids and their concentrations seem to be elevated dur- 
ing inflammation [6,8-IO]. The process by which the sIL-6R is 
formed is under investigation. After expression in COS-7 cells 
the membrane-bound form can be quantitatively released into 
the medium particularly upon treatment of the cells with 4p- 
phorbol 12-myristate-13-acetate [I 11. This indicates that the 
sIL6-R is formed by limited proteolysis (‘shedding’) and 
that this process is regulated by protein kinase C [ll-131. 
Recently, however, an alternatively spliced mRNA coding 
for a sIL-6R was also detected in human T and B cells and 
macrophages [14,15]. The sIL-6R purified from human plas- 
ma also contains a protein formed through differential splic- 
ing [16]. 
After binding to its hepatic receptor, IL-6 is internalized 
and degraded intracellularly [17,18]. This leads to a down- 
regulation of the surface expression of the IL-6 receptor 
[18]. We have recently demonstrated that the signal transducer 
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gp130 is a crucial component for this endocytosis and that a 
di-leucine internalization motif within its cytoplasmic domain 
is important for both internalization and ligand-induced 
downregulation [19,20]. Since the sIL-6R binds IL-6-depend- 
ently to a soluble form of gpl30 [21,22] and since the IL-61 
sIL-6R complex acts agonistically on cells expressing gp130 at 
the cell surface, we wished to determine whether such a com- 
plex is also internalized. 
2. Materials and methods 
2.1. Chemicals 
Human recombinant IL-6 (1.5 X lo6 B-cell stimulatory factor-2 
units/mg protein) was prepared as described by Arcone et al. [23] 
and kindly provided by J. Miillberg (Aachen, Germany). The biolog- 
ical activity of IL-6 was tested using the B9 proliferation assay [24]. 
Fetal calf serum (FCS) was from Seromed, Dulbecco’s modified Eagle 
medium (DMEM) and DMEMIFl2 media were from Gibco. Leupep- 
tin and monensin were from Boehringer Mannheim and Calbiochem, 
respectively. Bolton and Hunter reagent (N-succinimidyl-3-(4-hy- 
droxy-5-[1251]iodophenyl) propionate); 74 TBq/mmol) was purchased 
from Amersham International. 
2.2. Expression, purification and iodination of the sIL-6R 
The construction of the baculovirus transfer vector pVLSIR1 that 
codes for the extracellular part of the human IL-6R, the production of 
recombinant baculoviruses, the expression of the sIL-6R into super- 
natants of virus-infected S. frugiperda cells and its purification were 
recently described [25]. The recombinant protein was iodinated with 
Bolton and Hunter reagent to a specific activity of about 1 MBq/pg 
[26]. The iodinated sIL-6R was stored in aliquots at -20°C and re- 
tained its biological activity as determined by the induction of hap- 
toglobin in HepG2-IL-6 cells [25]. 
2.3. CeN culture 
The establishment of stably transfected Madin-Darby canine kidney 
cells expressing gp130 was recently described [27]. The cells were cul- 
tured in DMEM containing 10% FCS, 60 mg/l penicillin and 100 mg/l 
streptomycin. Human hepatoma cells HepG2 and fibrosarcoma ceils 
2flGH (a kind gift from Dr. S. Pelleerini. Pasteur Institute. Paris 1281) 
were grdwn in bMEMIFl2 and DEEM, respectively, supplemehtei 
as above. For binding and internalization experiments, cells were 
seeded in 24-well plates and grown for 2-3 days until they reached 
about 90% confluency. 
2.4. Binding and internalization studies 
All studies were performed in binding medium: DMEM containing 
no bicarbonate, 0.2% bovine serum albumin and 20 mM HEPES, pH 
7.2. 1251-sIL-6R at a concentration of 10 ng/ml was incubated with the 
appropriate amount of IL-6 overnight at 4°C in binding medium. 
Before the experiment, cells were washed with ice-cold binding me- 
dium and 200 l.d of the radioactive sample was added to each well. 
Binding was allowed for 2 h at 4°C. Surface-bound sIL-6R was eluted 
after three washes with binding medium by incubation for 5 min in 
0.5 M NaCl, pH 1. This treatment released more than 94% of surface- 
bound ligand (data not shown). In internalization studies, cells were 
rapidly warmed to 37°C after the initial binding step and incubated 
for different times in a waterbath. After incubation, surface-bound 
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ligand was eluted as above and in order to determine internalized 
ligand cells were lysed in 1 M NaOH. 
2.5. Degradation studies 
After binding of 1251-sIL-6R/IL-6 to HepG2 cells at 4°C for 2 h the 
temperature was shifted to 37°C and cells were incubated for 1 h at 
37°C. Ligand was removed and cells were washed three times with 
warm binding medium. Then 200 ~1 binding medium was added to 
each well and incubation continued for up to 6 h. Supernatants were 
removed and mixed with an equal volume of 20% trichloroacetic acid. 
Samples were cooled on ice and spun in an Eppendorf centrifuge. 
Radioactivity was measured in supernatants (trichloroacetic acid-sol- 
uble), sediments (trichloroacetic acid-precipitable) and cell lysates 
after dissolution in 1 M NaOH. Inhibition studies were performed 
by including 20 kg/ml leupeptin, 20 mM ammonium chloride or 100 
pM monensin during the 6 h incubation [29,30]. 
3. Results 
The interaction of a complex of IL-6 and the sIL-6R with 
cells expressing the signal transducer gp130 was investigated 
in MDCK cells that had been stably transfected with an ex- 
pression vector coding for gp130 (MDCK-gp130) [27]. 1251- 
sIL-6R at a concentration of 10 ng/ml was incubated with 
increasing concentrations of IL-6 (2 &ml-2 kg/ml) at 4°C 
for 18 h and then added to non-transfected MDCK and to 
MDCK-gp130 cells for 2 h. After washing, surface-bound 
ligand was eluted at pH 1 and radioactivity was measured 
in a y-counter. MDCK-gp130 cells bound ‘251-sIL-6R in an 
IL-6 dependent manner (Fig. lA, 0). Control MDCK cells 
also showed binding, however, at a sixfold lower level (Fig. 
lA, 0). This is explained by the fact that MDCK cells express 
endogenous gp130 [27]. We conclude that a complex of IL-6 
and the sIL-6R can bind to cell-surface gp130. This binding 
was saturated at 1 kg/ml IL-6. Therefore, this concentration 
was used throughout the internalization studies. 
For these studies, cells after ligand binding at 4°C were 
shifted to 37°C for 30, 60, 90 and 120 min. Internalized IL- 
6/1251-sIL-6R was measured as the radioactive fraction that 
became resistant to the acid wash. Within 60 min of incuba- 
tion the amount of ligand bound at time-point 0 was endocy- 
tosed by MDCK-gp130 cells (Fig. 1B). Thus, we conclude 
that the IL-6/sIL-6R complex is effectively internalized via 
gp130. 
In order to exclude the possibility that the observed inter- 
nalization is an artifact of transfected cells overexpressing the 
signal transducer, we analyzed binding and internalization in 
two human cell lines, hepatoma cells HepG2 expressing the 
IL-6R and gp130 and fibrosarcoma cells 2ffGH expressing 
only gp130 [31]. The latter cells are IL-6 responsive when 
stimulated with IL-6 and the sIL-6R [31]. Both cell lines 
were able to bind (data not shown) and internalize ‘251-sIL- 
6R in an IL-6 dependent manner at concentrations similar to 
those found with MDCK-gp130 cells (Fig. 2). However, the 
amount of sIL-6R bound and endocytosed was considerably 
smaller in 2fTGH cells (Fig. 2, 0) than in HepG2 cells (Fig. 2, 
??), indicating that 2fTGH cells have lower levels of endogen- 
ous gp130. 
In HepG2 cells we further studied the fate of internalized 
1251-sIL-6R. As indicated in Fig. 3A, cell-associated radioac- 
tivity decreased steadily during a 6 h chase (squares). Simul- 
taneously, there was an increase in radioactive material re- 
leased into the supernatant. Of this about 78% was secreted 
as trichloroacetic acid-soluble material (Fig. 3A, circles), 
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Fig. 1. (A) Binding of ‘251-sIL-6R. MDCK and MDCK-gp130 cells 
were incubated with 10 n&ml ‘251-sIL-6R and different concentra- 
tions of IL-6 for 2 h at 4°C as indicated. Cells were washed three 
times with binding medium and surface-bound ligand was eluted 
with 0.5 M NaCl, pH 1 for 5 min. Eluted radioactivity was meas- 
ured in a y-counter. The data are representative of four independent 
experiments. (0) MDCK, (0) MDCK-gp130. (B) Internalization of 
‘251-sIL-6R. MDCK and MDCK-gp130 cells were incubated with 
10 ng/ml 1251-sIL-6R and 1 pg/ml of IL-6 for 2 h at 4”C, shifted to 
37°C for the times indicated, cooled on ice and washed three times 
with binding medium. Surface-bound ligand was eluted as above. 
Internalized ‘251-sIL-6R was determined after dissolving the cells in 
1 M NaOH. Non-specific uptake was determined in the absence of 
IL-6 and subtracted. The data are representative of two independent 
experiments. Open symbols, surface-bound ligand; closed symbols, 
internalized ligand; squares, MDCK-gpl30; triangles, MDCK. 
whereas 22% was trichloroacetic acid-insoluble (Fig. 3A, tri- 
angles). Thus, obviously a large fraction of internalized ligand 
is degraded intracellularly. 
To study whether the degradation of 1251-sIL-6R occurs 
within the lysosomes, inhibitors of lysosomal function were 
added during the degradation study (Fig. 3B). The cysteine- 
proteinase inhibitor leupeptin at a concentration of 20 &ml 
slightly decreased the rate of degradation of ‘251-sIL-6R by 
about 30% (Fig. 3B, diamonds). However, at 6 h the lysoso- 
motropic agent ammonium chloride at 20 mM as well as 
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Fig. 2. Internalization of ‘251-sIL-6R by HepG2 and 2fTGH cells. 
Cells were incubated with 10 @ml ‘251-sIL-6R and different con- 
centrations of IL-6 for 2 h at 4°C as indicated. Cells were then 
shifted to 37°C for 1 h, washed three times with ice-cold-binding 
medium and surface-bound ligand was eluted at pH 1. Internalized 
ligand was determined after dissolving the cells in 1 M NaOH. The 
data are representative of two independent experiments. (w) HepG2; 
(0) 2ffGH. 
monensin at 100 FM significantly inhibited the degradation 
process by 75 and 80%, respectively (Fig. 3B, triangles and 
squares). 
4. Discussion 
Cytokines are important regulators of many different phys- 
iologic processes, such as cell proliferation, growth inhibition, 
cell death, cell differentiation and migration. Dysregulation of 
cytokine production often leads to pathological situations, 
such as inflammation, tumor growth and metastasis, and de- 
velopment of fibrosis. Therefore, cytokine synthesis and cyto- 
kine receptor levels must be tightly regulated. This is mainly 
achieved by a complex control of gene transcription. How- 
ever, efficient mechanisms for removing cytokines from the 
blood circulation must also exist in order to protect the or- 
ganism from over-stimulation. 
For a number of cytokine receptors, soluble forms were 
found in plasma and other biological fluids. These soluble 
receptors are either formed by proteolytic cleavage or by dif- 
ferential splicing [32]. For the sIL-6R both mechanisms of 
formation have been described [12,14,15]. Whereas most sol- 
uble cytokine receptors are antagonists since they compete 
with membrane-bound receptors for binding of the ligand 
[32], the sIL-6R is peculiar because after binding its ligand 
it acts agonistically on cells that express the signal transducer 
gp130 [2,6,7]. The fact that essentially all cells investigated so 
far do express gp130 suggests that a complex of IL-6 and the 
sIL-6R has a much broader spectrum of target cells than IL-6 
alone. Therefore, the means by which the organism controls 
the level of circulating soluble receptors are of interest. 
We have recently reported that the sIL-6R after intravenous 
injection into rats rapidly accumulates in liver, muscle, skin 
and kidneys [25]. However, the mechanisms by which the cells 
of these organs bind the sIL-6R were not investigated. We 
show in this paper that cells expressing gp130 are capable of 
binding and internalizing the sIL-6R in the presence of IL-6, 
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suggesting that the IL-6/sIL-6R complex is internalized via 
gp130. This is in agreement with recent results from our lab- 
oratory which have demonstrated that the cytoplasmic part of 
gp130 but not of the IL-6R is necessary for efficient IL-6 
internalization and IL-6R down-regulation [ 191. The identifi- 
cation of a di-leucine internalization motif within this intra- 
cellular part of gp130 indicates that the endocytosis of the IL- 
6/sIL-6R/gpl30 complex occurs by receptor-mediated endocy- 
tosis via clathrin-coated pits [20]. It is well known that recep- 
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Fig. 3. (A) Degradation of ‘251-sIL-6R in HepG2 cells. Cells were 
incubated with 10 ng/ml of 12SI-sIL-6R for 2 h at 4°C and then for 
1 h at 37°C in the presence and absence of 100 nM of IL-6. Cells 
were washed three times and incubated in binding medium for dif- 
ferent times as indicated. Degradation of lz51-sIL-6R was measured 
in the supematant after trichloroacetic acid precipitation of the 
medium (acid-soluble radioactivity, circles). Acid-precipitable radio- 
activity (triangles) was measured in sediments. Cell-associated radio- 
activity (squares) was counted after dissolving the cells in 1 N 
NaOH. Non-specific degradation was determined in the absence of 
IL-6 and subtracted. The data are representative of three independ- 
ent experiments. (B) The degradation study was performed as de- 
scribed above in either the absence (circles) or presence of 20 @ml 
of leupeptin (diamonds), 20 mM ammonium chloride (triangles) or 
100 pM monensin (squares) during the final incubation at 37°C. 
Degradation was calculated as percentage of total cell-associated 
radioactivity at time point 0. The data are representative of two in- 
dependent experiments. 
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tor-mediated endocytosis is important for the cellular uptake 
of many biologically active molecules. However, to our 
knowledge, this report is the first to demonstrate directly en- 
docytosis of a soluble cytokine receptor/ligand complex. 
35% of the internalized sIL-6R was degraded intracellularly 
over 6 h. This is a rather slow process when compared to the 
degradation of labeled IL-6 by HepG2 cells which is almost 
complete after 3 h (Graeve et al., unpublished observation). 
This indicates that the degradation of the sIL-6R is slower 
than that of IL-6. Future studies are necessary to elucidate 
the reason for this difference. The partial inhibition of the 
degradation of the IL-6/sIL-6R complex by leupeptin, ammo- 
nium chloride and monensin suggests that this degradation 
takes place in a lysosomal compartment. 
So far, the endocytosis of IL-6 and the sIL-6R has only 
been studied in liver parenchymal cells and cells of mesen- 
chymal origin. It is currently unknown whether the same 
process also occurs in hematopoietic cells like monocytesl 
macrophages and B- or T-lymphocytes. We hypothesize that 
essentially all cells are capable of endocytosing IL-6 and its 
soluble receptor as long as they express gp130 on their plasma 
membrane. 
The importance of the endocytosis of cytokines and their 
soluble receptors for signalling events and for the understand- 
ing of pathological situations is still unclear. In a recent re- 
port, two chimeric receptors consisting of the extracellular 
part of the epidermal growth factor receptor and the intracel- 
lular part of c-Ros and containing either the transmembrane 
domain of the epidermal growth factor receptor or of c-Ros 
were found not only to differ in their internalization efficien- 
cies but also to exhibit opposite effects on cell growth [33]. 
This study suggests that the internalization of signalling com- 
ponents has profound effects on the biological response. 
Whether this is also the case for the IL-6 signal transduction 
is currently under investigation. 
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